Innovent Biologics - Bamboo Works - China stock insights for global investors

FAST NEWS: Lepu Biopharma to raise $32 million in share sale

Fri, 17 May 2024 05:34:10 +0000

The Latest: Innovative drug maker Lepu Biopharma Co. Ltd. (2157.HK) announced on Friday it will place up to 51.17 million shares, or about 2.99% of its overall issued share capital, for a sale price of HK$4.58 per share. Looking Up: The company expects to receive approximately 230 million yuan ($32 million) in net proceeds from the.....

The post FAST NEWS: Lepu Biopharma to raise $32 million in share sale appeared first on Bamboo Works.

FAST NEWS: Innovent Bio’s revenue soars on strong cancer treatment sales

Fri, 03 Nov 2023 05:55:46 +0000

The latest: Biotech company Innovent Biologics Inc. (1801.HK) announced on Thursday it recorded product revenue of more than 1.6 billion yuan ($2.2 million) in the third quarter, up 45% year-on-year, and also up significantly from the previous quarter. Looking up: The revenue jump was powered by continued strong sales for the company’s Tyvyt Sintilimab injection, used to.....

The post FAST NEWS: Innovent Bio’s revenue soars on strong cancer treatment sales appeared first on Bamboo Works.

Adlai Nortye dives in Nasdaq debut, as key product faces hurdles

Fri, 13 Oct 2023 03:46:49 +0000

Shares of the drug maker that licenses its products from other companies lost more than half their value in the two weeks after their listing Key Takeaways: 　 By Molly Wen Weak sentiment has cast a cloud over Chinese stocks this year, and it’s even chillier for unprofitable biotech companies that were always a difficult.....

The post Adlai Nortye dives in Nasdaq debut, as key product faces hurdles appeared first on Bamboo Works.

RemeGen hopes for pain relief from expanded drug uses

Wed, 20 Sep 2023 22:39:59 +0000

The innovative drug company has so far brought only two products to market, and its high sales expenses make investors worry about fallout from an anti-corruption drive Key Takeaways: 　 By Molly Wen An anti-corruption campaign targeting China’s healthcare sector has shone a harsh spotlight on pharmaceutical companies that invest heavily to inject their drugs.....

The post RemeGen hopes for pain relief from expanded drug uses appeared first on Bamboo Works.

FAST NEWS: Innovent Bio to raise HK$2.4 billion in share placement

Tue, 12 Sep 2023 06:10:17 +0000

The latest: Biotech company Innovent Biologics Inc. (1801.HK) announced on Tuesday it will place 68 million new shares, representing approximately 4.22% of its enlarged share capital, to raise about HK$2.36 billion ($302 million). Looking up: The placement will give Innovent significant new funding to accelerate its R&D of several priority preclinical and clinical programs across its pipeline, and.....

The post FAST NEWS: Innovent Bio to raise HK$2.4 billion in share placement appeared first on Bamboo Works.

BeiGene goes for global growth with sales and R&D push

Thu, 11 May 2023 04:21:50 +0000

The maker of cancer drugs is ploughing most of its rising revenues into research and sales, as it prioritizes expansion over profits for now Key Takeaways: 　 By Ellie Si It ranks as China’s market leader for innovative cancer drugs and is rapidly raising its global profile. But BeiGene Ltd. (BGNE.US; 6160.HK; 688235.SH) has been.....

The post BeiGene goes for global growth with sales and R&D push appeared first on Bamboo Works.

Missing the Covid boat, Junshi stumbles back to old business

Wed, 10 May 2023 04:09:07 +0000

Despite developing an oral drug to treat Covid, the biotech company’s revenue fell sharply and its net loss widened by nearly 40% in the first quarter Key Takeaways: 　 By Emily Chan Call it the Covid boom that never came. Shanghai Junshi Biosciences Co. Ltd. (1877.HK; 688180.SH) was expecting a revenue bump from its oral.....

The post Missing the Covid boat, Junshi stumbles back to old business appeared first on Bamboo Works.

Lepu Biopharma gets taste of spring with first revenues

Thu, 23 Mar 2023 03:38:53 +0000

The ADC-focused drug company logged its first-ever sales late last year, kicking of the next phase of its development Key Takeaways: 　 By Molly Wen After years of cash burning to support its drug development and Hong Kong listing, Lepu Biopharma Co. Ltd. (2157.HK) has entered a new phase as it graduates from the ranks.....

The post Lepu Biopharma gets taste of spring with first revenues appeared first on Bamboo Works.

Losses Mount at InnoCare but Cash Cushion Dulls the Pain

Fri, 18 Nov 2022 03:54:00 +0000

The cancer drug developer logged another loss in the latest quarter but a cash pile of more than 9.2 billion yuan can sustain its business for the next five years Key Takeaways: InnoCare’s drug sales soared after its key product was approved for Chinese medical insurance coverage, but hefty foreign exchange losses pushed the accounts.....

The post Losses Mount at InnoCare but Cash Cushion Dulls the Pain appeared first on Bamboo Works.

Surging Beigene Catches Case of Forex Flu

Mon, 14 Nov 2022 03:39:56 +0000

The drug maker’s net loss grew in the third quarter due to weakness in the Chinese yuan, even as its revenue nearly doubled Key Takeaways: Surging sales for its two self-developed drugs fueled an 88% rise in BeiGene’s third-quarter revenue, but over $100 million in foreign exchange losses caused its net loss to also widen.....

The post Surging Beigene Catches Case of Forex Flu appeared first on Bamboo Works.

New Drugs Approvals Bring No Relief for Ailing Innovent Bio

Mon, 17 Oct 2022 04:22:06 +0000

The innovative drug maker has been approved to sell two more cancer drugs in China, but that hasn’t lifted its stock price Key Takeaways: Innovent Bio has brought several drugs to market in recent years, including two announced last week, but is still losing money with no profits in sight The company has overhauled its.....

The post New Drugs Approvals Bring No Relief for Ailing Innovent Bio appeared first on Bamboo Works.

Lepu Biopharma Marches Towards First Sales as Costs Mount

Thu, 06 Oct 2022 05:04:58 +0000

Company’s Puyouheng cancer immunotherapy drug was approved for two indications in China, becoming its first commercialized product Key Takeaways: Lepu Biopharma will incur more operational costs as it builds up its production capacity and sales and marketing teams to commercialize its first approved product The company’s stock surged after it said it would list on.....

The post Lepu Biopharma Marches Towards First Sales as Costs Mount appeared first on Bamboo Works.